Arch Therapeutics, Inc. Share · US03939W2089 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Arch Therapeutics, Inc.
No Price
Company Profile for Arch Therapeutics, Inc. Share
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Company Data
Name Arch Therapeutics, Inc.
Company Arch Therapeutics, Inc.
Website
https://www.archtherapeutics.com
Primary Exchange 
UTC
UTC
ISIN US03939W2089
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Terrence W. Norchi
Country United States of America
Currency USD
Employees 0,0 T
Address 235 Walnut Street, 01702 Framingham
IPO Date 2013-01-02
Stock Splits
| Date | Split |
|---|---|
| 18.01.2023 | 1:200 |
| 28.05.2013 | 11:1 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | ARTH |
More Shares
Investors who hold Arch Therapeutics, Inc. also have the following shares in their portfolio:
